Phase I Study of Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

Condition:   Metastatic Breast Cancer Interventions:   Biological: huMNC2-CAR44 CAR T cells;   Biological: huMNC2-CAR44 CAR T cells @ RP2D Sponsors:   Minerva Biotechnologies Corporation;   Fred Hutchinson Cancer Research Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials